Meeting Coverage

A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among...

The DESTINY-Breast07 trial will test trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer, as a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion...

The phase 3 ELEVATE-RR trial was a head-to-head comparison of acalabrutinib versus ibrutinib in previously treated patients with chronic lymphocytic leukemia. The first results of this study demonstrated that acalabrutinib had...

Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in patients with chronic lymphocytic leukaemia (CLL). Results from the 4-year follow-up of the ELEVATE-TN study...

The addition of durvalumab after chemoradiation (CRT) in unresectable stage 3 non-small cell lung cancer (NSCLC) can be safely delivered in elderly patients ≥70 years with comparable improvement in overall survival (OS), as...

Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...

Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has durable...

Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has just as durable...

Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...

For a presentation at ASCO 2021, John Seymour, PhD, Professor at the Peter MacCallum Cancer Centre of the Royal Melbourne Hospital and University of Melbourne in Australia, discussed six FDA-approved agents or drug...

For a review presented at ASCO 2021, Sonali M. Smith, MD, FASCO, Elwood V. Jensen Professor in Medicine and Chief of the Section of Hematology/Oncology at the University of Chicago, discussed the findings of two studies focused...

TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...

Genetic testing for BRCA1/2 mutations is recommended for all women with ovarian cancer, given the important implications for treatment and prognosis, according to the Caitlin E. Taylor, MD, lead author of a paper presented at...

It has long been identified that Black women with ovarian cancer have worse overall survival when compared to White women, explains Deanna L Huffman, DO, Department of Internal Medicine, Allegheny Health Network, in Pittsburgh....

Effective patient-clinician communication (PCC) is central to the delivery of high-quality care, according to the National Cancer Institute (NCI), and it becomes even more crucial in the cancer setting where patients deal with...

A better understanding of the burden of treatment side effects in patients with gynecological malignancies could help guide symptom interventions and oncologic therapy decision-making, according to Ashley D. Hickman, MD, the...